Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.58 |
| ▸ | CDK4 | P11802 | 5/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.58 |
| ▸ | KDR | P35968 | 5/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.51 |
| ▸ | PLK1 | P53350 | 2/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 3/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.43 |
| ▸ | GSK3B | P49841 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | IKBKB | O14920 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.43 |
| ▸ | PRKCG | P05129 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4819158 | 0.88 | CDK2 (0.60) | CDK2CDK4CCNE1KDRPTK2 | |
| SCHEMBL4821591 | 0.78 | CDK2 (0.72) | CDK2CDK4CDK1IKBKBSYK | |
| SCHEMBL6596500 | 0.76 | CDK2 (0.64) | CDK2CDK4CCNE1KDRPTK2 | |
| SCHEMBL4821808 | 0.76 | KDR (0.53) | CDK2CDK4CCNE1KDRPTK2 | |
| SCHEMBL5098405 | 0.76 | CDK2 (0.72) | CDK2CDK4CCNE1KDRPTK2 | |
| SCHEMBL6593493 | 0.73 | KDR (0.53) | CDK2CDK4CCNE1KDRPTK2 | |
| SCHEMBL6245628 | 0.72 | CDK2 (0.69) | CDK2CDK4CCNE1KDRPTK2 | |
| SCHEMBL4824472 | 0.72 | CDK2 (0.63) | CDK2CDK4CDK1GSK3BIKBKB | |
| SCHEMBL4824463 | 0.71 | CDK2 (0.58) | CDK2CDK4CCNE1CDK1GSK3B | |
| SCHEMBL2283254 | 0.71 | CDK2 (0.73) | CDK2CDK4CCNE1PLK1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446105-B2 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2008-11-04 | — | — | US | disclosed |
| US-20050119291-A1 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | disclosed |
| EP-1485374-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003076433-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119291-A1 | Pyrimidine compounds | TYMP, TYMS, CCNT1 | CDK2 22/4885CDK4 47/4885CCNE1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.